Introduction Low cardiac output syndrome (LCOS) is a significant cause of morbidity and the
leading cause of mortality after pediatric cardiac surgery. Levosimendan has been shown …

BACKGROUND Low cardiac output syndrome (LCOS) after congenital cardiac surgery has
an incidence of up to 25%. Preventing and treating LCOS is of pivotal importance as LCOS …

Purpose To evaluate the safety and efficacy of levosimendan in neonates with congenital
heart disease undergoing cardiac surgery with cardiopulmonary bypass (CPB). Methods …

Low cardiac output is one of the most common complications after cardiac surgery.
Levosimendan, a new inotrope agent, has been demonstrated in adult patient to be an …

Low-Cardiac-Output Syndrome (LCOS) early after cardiopulmonary bypass (CPB) is a well-
known problem in the postoperative course after complex congenital heart surgery, which …

Background Low cardiac output syndrome remains a serious complication, and accounts for
substantial morbidity and mortality in the postoperative course of paediatric patients …

Background: Levosimendan, a calcium sensitizer, enhances the myocardial function by
generating more energy-efficient myocardial contractility than that achieved through …

Levosimendan increasingly has been used to treat heart failure and cardiac dysfunction in
pediatric patients. Currently, there is only limited evidence that this drug positively affects …

Objective The aim was to test the hypothesis that preoperative infusion of levosimendan
would decrease patients' cardiac biomarker profiles during the immediate postoperative …

Structured clinical question In postoperative congenital heart disease children (population),
is levosimendan (intervention) better than milrinone (comparison) in improving cardiac …